Treatment with RANTES antagonists reduced tissue damage in IRI-related diseases such as myocardial infarction or brain infarction by significant decrease in infiltrating inflammatory cells, such as neutrophils, macrophages and lymphocytes7, 10. The gene discussed is CCL5; the disease is myocardial infarction.